{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:33:12Z","timestamp":1788201192287,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"am","delay-in-days":290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.autrev.2021.103013","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T17:17:25Z","timestamp":1639675045000},"page":"103013","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management"],"prefix":"10.1016","volume":"21","author":[{"given":"P.","family":"Decker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moulinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pontille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cravat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Carvalho Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.103013_bb0005","series-title":"StatPearls [Internet]","article-title":"Anatomy, connective tissue","author":"Kamrani","year":"2020"},{"key":"10.1016\/j.autrev.2021.103013_bb0010","series-title":"StatPearls [Internet]","article-title":"Physiology, connective tissue","author":"Nezwek","year":"2020"},{"issue":"6","key":"10.1016\/j.autrev.2021.103013_bb0015","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/0952-7915(94)90010-8","article-title":"T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance","volume":"6","author":"Miller","year":"1994","journal-title":"Curr Opin Immunol"},{"issue":"7042","key":"10.1016\/j.autrev.2021.103013_bb0020","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature03724","article-title":"Cellular and genetic mechanisms of self tolerance and autoimmunity","volume":"435","author":"Goodnow","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2021.103013_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2021.103013_bb0030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMra020100","article-title":"The effect of infections on susceptibility to autoimmune and allergic diseases","volume":"347","author":"Bach","year":"2002","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.smim.2011.01.015","article-title":"Genetic predisposition to autoimmunity--what have we learned?","volume":"23","author":"Rai","year":"2011","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2021.103013_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0065-2776(05)87004-X","article-title":"Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse","volume":"87","author":"Haskins","year":"2005","journal-title":"Adv Immunol"},{"key":"10.1016\/j.autrev.2021.103013_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2013.06.003","article-title":"Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen","volume":"44","author":"Horai","year":"2013","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0050","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.V54.5.1131.1131","article-title":"Monocyte-mediated destruction in the presence of serum of red cells coated with antibody","volume":"54","author":"Kurlander","year":"1979","journal-title":"Blood."},{"key":"10.1016\/j.autrev.2021.103013_bb0055","series-title":"Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy [Internet]","volume":"Vol. 2015","author":"Berentsen","year":"2015"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1172\/JCI117371","article-title":"Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo","volume":"94","author":"Kramers","year":"1994","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.semnephrol.2011.06.009","article-title":"Lupus nephritis: role of antinucleosome autoantibodies","volume":"31","author":"van der Vlag","year":"2011","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/en.2008-0878","article-title":"Characterization of thyrotropin receptor antibody-induced signaling cascades","volume":"150","author":"Morshed","year":"2009","journal-title":"Endocrinology."},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0075","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0080","first-page":"509","article-title":"FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus","volume":"10","author":"Batteux","year":"1999","journal-title":"Eur Cytokine Netw"},{"issue":"8","key":"10.1016\/j.autrev.2021.103013_bb0085","first-page":"3664","article-title":"IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies","volume":"194","author":"Anquetil","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/art.1780330505","article-title":"Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study","volume":"33","author":"ter Borg","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2021.103013_bb0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.1995.341","article-title":"Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice","volume":"48","author":"Ehrenstein","year":"1995","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2021.103013_bb0100","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jcla.21522","article-title":"Comparative study of immunofluorescent antinuclear antibody test and line immunoassay detecting 15 specific autoantibodies in patients with systemic rheumatic disease","volume":"26","author":"Lee","year":"2012","journal-title":"J Clin Lab Anal"},{"issue":"7050","key":"10.1016\/j.autrev.2021.103013_bb0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(58)91480-6","article-title":"Lacrimal and salivary precipitating antibodies in Sj\u00f6gren\u2019s syndrome","volume":"2","author":"Jones","year":"1958","journal-title":"Lancet Lond Engl"},{"issue":"7200","key":"10.1016\/j.autrev.2021.103013_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0140-6736(61)92430-8","article-title":"Precipitating autoantibodies in Sjogren\u2019s disease","volume":"2","author":"Anderson","year":"1961","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0125","first-page":"117","article-title":"Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus","volume":"102","author":"Clark","year":"1969","journal-title":"J Immunol Baltim Md 1950"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.1780170413","article-title":"Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen","volume":"17","author":"Mattioli","year":"1974","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2021.103013_bb0135","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1073\/pnas.81.7.1996","article-title":"The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs","volume":"81","author":"Wolin","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0140","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1084\/jem.167.5.1560","article-title":"A 52-kD protein is a novel component of the SS-A\/Ro antigenic particle","volume":"167","author":"Ben-Chetrit","year":"1988","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1172\/JCI114968","article-title":"Protein heterogeneity in the human Ro\/SSA ribonucleoproteins. The 52- and 60-kD Ro\/SSA autoantigens are encoded by separate genes","volume":"87","author":"Itoh","year":"1991","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2021.103013_bb0150","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.molimm.2005.04.013","article-title":"Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sj\u00f6gren\u2019s syndrome","volume":"43","author":"Ottosson","year":"2006","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0155","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/emboj\/20.9.2140","article-title":"The tripartite motif family identifies cell compartments","volume":"20","author":"Reymond","year":"2001","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.autrev.2021.103013_bb0160","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.20090585","article-title":"Loss of the lupus autoantigen Ro52\/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway","volume":"206","author":"Espinosa","year":"2009","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2005.11.029","article-title":"Autoantigen Ro52 is an E3 ubiquitin ligase","volume":"339","author":"Wada","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.autrev.2021.103013_bb0170","first-page":"1780","article-title":"The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3","volume":"181","author":"Higgs","year":"2008","journal-title":"J Immunol Baltim Md 1950"},{"issue":"7","key":"10.1016\/j.autrev.2021.103013_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011776","article-title":"Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors","volume":"5","author":"Higgs","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0180","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.celrep.2019.09.069","article-title":"STING-mediated IFI16 degradation negatively controls type I interferon production","volume":"29","author":"Li","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/imr.12363","article-title":"TRIM21: a cytosolic fc receptor with broad antibody isotype specificity","volume":"268","author":"Foss","year":"2015","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2021.103013_bb0190","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10875-007-9157-0","article-title":"Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies","volume":"28","author":"Strandberg","year":"2008","journal-title":"J Clin Immunol"},{"issue":"16","key":"10.1016\/j.autrev.2021.103013_bb0195","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1128\/MCB.01630-05","article-title":"Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein","volume":"26","author":"Sabile","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbrc.2011.12.010","article-title":"SS-A\/Ro52 promotes apoptosis by regulating Bcl-2 production","volume":"417","author":"Jauharoh","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.autrev.2021.103013_bb0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/cei.13211","article-title":"The Sj\u00f6gren\u2019s syndrome-associated autoantigen Ro52\/TRIM21 modulates follicular B cell homeostasis and immunoglobulin production","volume":"194","author":"Brauner","year":"2018","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2021.103013_bb0210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00296-010-1790-x","article-title":"The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sj\u00f6gren\u2019s syndrome","volume":"32","author":"Song","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/08916934.2012.732131","article-title":"Clinical associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies: diagnostic utility of their separate detection","volume":"46","author":"Men\u00e9ndez","year":"2013","journal-title":"Autoimmunity."},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0225","first-page":"686","article-title":"Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Retamozo","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.103013_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/832789","article-title":"Common and specific associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies in systemic lupus erythematosus","volume":"2013","author":"Men\u00e9ndez","year":"2013","journal-title":"ScientificWorldJournal."},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0235","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0240","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/rheumatology\/kes311","article-title":"Clinical pulmonary involvement in primary Sjogren\u2019s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data","volume":"52","author":"Palm","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2021.103013_bb0250","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","article-title":"A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sj\u00f6gren\u2019s syndrome-related interstitial lung disease in a Chinese population","volume":"37","author":"Dong","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0255","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cei.12341","article-title":"Ductal epithelial expression of Ro52 correlates with inflammation in salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"177","author":"Aqrawi","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0260","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.12058","article-title":"Ro52- and Ro60-specific B cell pattern in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"172","author":"Aqrawi","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001184","article-title":"Autoantigen TRIM21\/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sj\u00f6gren\u2019s syndrome is associated with B cell hyperactivity and type I interferon activity","volume":"6","author":"Hillen","year":"2020","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.autrev.2021.103013_bb0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2014-206297","article-title":"Interaction between innate immunity and Ro52-induced antibody causes Sj\u00f6gren\u2019s syndrome-like disorder in mice","volume":"75","author":"Szczerba","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2021.103013_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102935","article-title":"Immune response targeting Sj\u00f6gren\u2019s syndrome antigen Ro52 suppresses tear production in female mice","volume":"19","author":"Trzeciak","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"Suppl 112(3)","key":"10.1016\/j.autrev.2021.103013_bb0280","first-page":"41","article-title":"Immune response against the coiled coil domain of Sj\u00f6gren\u2019s syndrome associated autoantigen Ro52 induces salivary gland dysfunction","volume":"36","author":"Sroka","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"42","key":"10.1016\/j.autrev.2021.103013_bb0285","doi-asserted-by":"crossref","first-page":"36478","DOI":"10.1074\/jbc.M111.241786","article-title":"Anti-Ro52 autoantibodies from patients with Sj\u00f6gren\u2019s syndrome inhibit the Ro52 E3 ligase activity by blocking the E3\/E2 interface","volume":"286","author":"Espinosa","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032001","article-title":"Two major autoantibody clusters in systemic lupus erythematosus","volume":"7","author":"Ching","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2009.09472.x","article-title":"Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients","volume":"162","author":"Vera-Recabarren","year":"2010","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0300","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/0961203306073135","article-title":"Fine specificity of the Ro\/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun","volume":"16","author":"Popovic","year":"2007","journal-title":"Lupus."},{"issue":"8","key":"10.1016\/j.autrev.2021.103013_bb0305","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/jid.2008.453","article-title":"High Ro52 expression in spontaneous and UV-induced cutaneous inflammation","volume":"129","author":"Oke","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0310","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0961203313479420","article-title":"Autoantibodies to the functionally active RING-domain of Ro52\/SSA are associated with disease activity in patients with lupus","volume":"22","author":"Kvarnstr\u00f6m","year":"2013","journal-title":"Lupus."},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0315","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.3892\/etm.2017.4235","article-title":"Association of calreticulin expression with disease activity and organ damage in systemic lupus erythematosus patients","volume":"13","author":"Wang","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.autrev.2021.103013_bb0320","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fimmu.2020.00098","article-title":"TRIM21 dysfunction enhances aberrant B-cell differentiation in autoimmune pathogenesis","volume":"11","author":"Kunishita","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2021.103013_bb0325","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/ard.56.11.667","article-title":"Prevalence and clinical relevance of 52-kDa and 60-kDa Ro\/SS-A autoantibodies in Japanese patients with systemic sclerosis","volume":"56","author":"Fujimoto","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 91","key":"10.1016\/j.autrev.2021.103013_bb0330","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2021.103013_bb0335","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.autrev.2021.103013_bb0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-6-2","article-title":"Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis","volume":"6","author":"Parker","year":"2009","journal-title":"J Autoimmune Dis"},{"key":"10.1016\/j.autrev.2021.103013_bb0345","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","volume":"1\u20136","author":"Lee","year":"2021","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/ojra.2013.32017","article-title":"Associations with organ involvement and autoantibodies in systemic sclerosis: results from the Canadian scleroderma research group (CSRG)","volume":"3","author":"Tangri","year":"2013","journal-title":"Open J Rheumatol Autoimmune Dis"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0355","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2021.103013_bb0360","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2021.103013_bb0365","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/ar2276","article-title":"Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes","volume":"9","author":"Koenig","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0370","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.103013_bb0375","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2021.103013_bb0380","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated Antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.103013_bb0385","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct Antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0390","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2021.103013_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.autrev.2021.103013_bb0400","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0405","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cei.12914","article-title":"Ro52\/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies","volume":"188","author":"G\u00f3mez-Mart\u00edn","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0410","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2006.06.003","article-title":"Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis","volume":"27","author":"Hassan","year":"2006","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2021.103013_bb0415","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.103013_bb0420","series-title":"Mixed connective tissue diseses and antinuclear antibodies","first-page":"23","article-title":"Diagnostic criteria for classification of MCTD","author":"Sharp","year":"1987"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0425","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/kev300","article-title":"Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease","volume":"55","author":"Gunnarsson","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0430","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","article-title":"Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study","volume":"57","author":"Reiseter","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0435","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","article-title":"Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0440","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/ard.54.2.148","article-title":"Specificity of antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Chou","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.103013_bb0445","first-page":"1404","article-title":"Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sj\u00f6gren\u2019s syndrome","volume":"24","author":"D\u00f6rner","year":"1996","journal-title":"Hepatol Baltim Md"},{"issue":"8","key":"10.1016\/j.autrev.2021.103013_bb0450","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/rheumatology\/kep145","article-title":"Clinical significance of anti-Ro\/SSA-52 kDa antibodies: a retrospective monocentric study","volume":"48","author":"Hervier","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0455","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"9842","key":"10.1016\/j.autrev.2021.103013_bb0460","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216372","article-title":"Association of anti-Ro52 autoantibodies with interstitial lung disease in connective tissue diseases","volume":"80","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.103013_bb0470","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2021.04.020","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases","volume":"91","author":"Decker","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.103013_bb0480","first-page":"145","article-title":"Extraordinary antigenicity of the human Ro52 autoantigen","volume":"2","author":"Burbelo","year":"2010","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0485","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/08916939508995297","article-title":"Stress-induced cell surface expression and antigenic alteration of the Ro\/SSA autoantigen","volume":"22","author":"Igarashi","year":"1995","journal-title":"Autoimmunity."},{"issue":"9","key":"10.1016\/j.autrev.2021.103013_bb0490","first-page":"5345","article-title":"Anti-SSA\/Ro and anti-SSB\/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages","volume":"165","author":"Miranda-Car\u00fas","year":"2000","journal-title":"J Immunol Baltim Md 1950"},{"issue":"1","key":"10.1016\/j.autrev.2021.103013_bb0495","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1084\/jem.20041859","article-title":"Ro\/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block","volume":"201","author":"Salomonsson","year":"2005","journal-title":"J Exp Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:00Z","timestamp":1761600360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1568997221002950"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.103013","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.103013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103013"}}